NEW YORK (GenomeWeb) – Finnish molecular diagnostics firm Mobidiag announced today that it has signed a deal making Isogen Life Sciences the exclusive distributor of all its Amplidiag in vitro diagnostic products in Belgium, the Netherlands, Luxembourg, and Spain.
The Amplidiag line includes PCR-based tests for various gastrointestinal infections including two CE-IVD marked assays — Bacterial GE, which detects Campylobacter, Salmonella, Shigella, Yersinia, and five different Escherichia coli pathotypes; and Amplidiag C. difficile+27 for identifying toxin-producing Clostridium difficile — as well as the Amplidiag Easy automated platform that runs the tests. The firm also sells Amplidiag tests for H. pylori, stool parasites, and CarbaR+VRE, which identifies five major and clinically most relevant carbapenemase groups and two vancomycin resistance markers.
"Since Mobidiag's inception, we have been focusing our activity towards [the] Nordic region and France mainly," Mobidiag CEO Tuomas Tenkanen said in a statement. "We are now in a phase of great expansion and extending our European coverage with the support of reliable partners."
Last year, the company inked a deal giving Unilabs the right to market the Amplidiag products in Sweden and Norway. Tenkanen told GenomeWeb about a year ago that Mobidiag aims to bring its tests to the US market in 2017.